The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Making Sense of Drug Pricing Legislation

Making Sense of Drug Pricing Legislation

July 2, 2019 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The 116th Congress has introduced numerous pieces of legislation meant to reduce the impact of the cost of medicines and treatments on American patients. The ACR fully supports the goal of reducing the cost burden on patients and increasing access to treatments. The College has convened a working group on drug pricing and published a set of guiding principles that would help maximize rheumatology patients’ access to treatments. Stay tuned for updates about what happens to the various active bills in Congress.

You Might Also Like
  • ACR Responds to Drug Pricing Proposals
  • U.S. Lawmaker Launches Investigation into Pharma Drug Pricing
  • FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs
Also By This Author
  • Pediatric Rheumatology Learning at the 2019 ACR/ARP Annual Meeting

The College has closely monitored the introduced bills and voiced support for those that best align with its principles on drug pricing. The ACR’s position is that:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  1. All patients should have safe, convenient and affordable access to rheumatology treatments that control disease activity and prevent permanent joint and organ damage, thereby limiting disability and early death;
  2. Rational policies that mitigate rapid escalations in pricing of rheumatologic drugs must be adopted;
  3. Transparency should be encouraged in the policies used by pharmaceutical manufacturers, pharmacy benefit managers and health insurance companies to determine prescription drug prices;
  4. A safe and efficient biosimilar approval pathway and marketplace will improve access to treatment by lowering costs;
  5. Any comprehensive proposal to deal with rising drug prices must simultaneously address these primary concerns: cost to the healthcare system, continuity of care and out-of-pocket affordability for patients; and
  6. Patient access to physician-administered drugs can only be preserved by recognizing the rheumatologists’ role in providing specialized, continuous care.

You can review the College’s letters of support for qualifying legislation on the ACR’s Advocacy site. While on the ACR website, visit the ACR’s Legislative Action Center, where you can also tell Congress to reform prior authorization and step therapy, and boost DXA reimbursement and the pediatric subspecialty workforce.

Filed Under: Drug Updates, Legislation & Advocacy, Professional Topics Tagged With: Advocacy, American College of Rheumatology, drug, Legislation, rheumatology

You Might Also Like:
  • ACR Responds to Drug Pricing Proposals
  • U.S. Lawmaker Launches Investigation into Pharma Drug Pricing
  • FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs
  • WHO Drug Pricing Talks May Fail to End Secrecy, Activists Fear

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)